LONG BEACH, Calif. — As reported in today’s issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism and that these changes can be measured with a simple blood...
Latest News
DAVENPORT – The Sunshine Foundation, an organization that grants wishes to sick children, will bring to Central Florida 14 young people, mostly children, who were born with progeria, an illness that causes them to age prematurely. The organization’s annual Progeria Reunion will include a picnic and game day at the...
Seven years after the passage of a law advancing the interests of persons afflicted with rare diseases, patients, and other stakeholder groups are still clamoring for government support in terms of adequate funding and implementation of the Integrated Rare Diseases Management Program Strategic Plan. “Persons suffering from rare diseases, sometimes...
CHICAGO, Illinois – Researchers have identified a new way to screen genes that cause several different types of cancers to grow, identifying particularly promising targets for precision oncology in oral and esophageal squamous cancers. The study, published in this month’s issue of Cell Reports, used 3-dimensional models of organ tissues called organoids...
WALTHAM, Mass. — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson’s disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents. As a...
Brentford, UK – GSK plc (LSE/NYSE: GSK) today announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma. These data were presented...
MISSISSAUGA, Canada – GSK announced that Health Canada has accepted into review the New Drug Submission (NDS) for momelotinib, a potential new medicine with a differentiated mechanism of action that may help address the significant medical needs of myelofibrosis patients, especially those with anemia. The NDS is based on key...
BEVERLY HILLS, Calif.- GT Biopharma, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology: TriKE™ for cancer and infectious diseases, today announced the addition of a new clinical trial site for its ongoing...
BEVERLY HILLS, Calif. – GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform, is pleased to announce the enrollment of Patient 10 in its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial...
BEVERLY HILLS, Calif. – GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform, announced today additional interim results from its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial for the treatment of...